Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 61
Filter
1.
Cureus ; 15(5): e39669, 2023 May.
Article in English | MEDLINE | ID: mdl-37261368

ABSTRACT

Sarcomatoid carcinoma (SC) is a rare primary malignant tumor belonging to the group of non-small cell lung cancer (NSCLC). The diagnosis requires proper tumor sampling to exclude sarcoma, which is the main differential diagnosis. However, the prognosis of these tumors is poor, with a median survival rate lower than other NSCLC cases, mainly due to their aggressiveness and resistance to chemotherapy, especially platinum salts. In this report, we discuss a case of a 62-year-old male patient who presented at admission with hemoptysis and dyspnea. The diagnosis process involved thoracic computed tomography (CT) and fiberoptic bronchoscopy, which revealed tissue thickening at the carina and a mass extending from the lower end of the trachea to the carina, which was confirmed by biopsy. Unfortunately, despite receiving neoadjuvant radiotherapy and having endotracheal prosthesis, the patient succumbed to tumor progression. Our case highlights the aggressive nature of this tumor and underscores the importance of early detection.

2.
Cureus ; 15(3): e36880, 2023 Mar.
Article in English | MEDLINE | ID: mdl-37123706

ABSTRACT

The diagnosis of chronic lymphoid leukemia (CLL) is essentially based on a blood smear and immunophenotyping by flow cytometry of circulating lymphocytes. Unusual locations of the disease can sometimes be observed. Here we report the case of a patient admitted for the management of pleurisy. The pleural effusion was lymphocytic exudate; histological examination of the pleural biopsy along with immunohistochemistry helped yield the diagnosis of secondary localization of CLL. The patient was transferred to the Internal Medicine department where chemotherapy was introduced.

3.
Zookeys ; (774): 41-52, 2018.
Article in English | MEDLINE | ID: mdl-30034262

ABSTRACT

An updated and corrected checklist of species of ladybird beetles (Coleoptera: Coccinellidae) known in Algeria now contains 75 species belonging in ten tribes. New country records include the European species Oenopia conglobata and the invasive Asian species Harmonia axyridis. Sampling data is provided for 14 species found during a faunistic survey performed mostly in agroecosystems, together with host plant and prey species.

4.
Therapie ; 71(6): 535-539, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27692979

ABSTRACT

Anaphylactic reactions are often induced by drugs, and the most frequent ones are penicillin derivates. The concurrence of acute coronary syndrome with hypersensitivity and anaphylactic or anaphylactoid reactions constitutes the Kounis syndrome. We report a case of a coronary stent thrombosis with a fatal outcome complicating an anaphylactic shock induced by amoxicillin-clavulanic acid association. A 58-year-old woman with a history of triple coronary stenting was treated by amoxicillin/clavulanic acid association for pharyngitis. One hour after the first drug intake, she developed an anaphylactic shock with acute constricting chest pain. She received intravenous hydrocortisone and was transferred to emergency department. The patient received epinephrine intravenously with fluid perfusion and oxygen. Electrocardiogram showed Pardee waves in the anterior precordial leads. Cardiac enzyme levels (troponin I) were disturbed. The patient was transferred to the coronary care unit with a diagnosis of acute myocardial infarction. The coronary angiography revealed anterior interventricular stent thrombosis. The patient experienced a cardiogenic shock with an important hemodynamic repercussion, and she died few hours later despite emergency care. The responsibility of amoxicillin-clavulanic acid association was retained in the genesis of this anaphylactic shock in front of a suggestive delay, a compatible evolution and a high semiotic score. Amoxicillin/clavulanic acid use may cause Kounis syndrome. The use of epinephrine is a challenging decision. We suggest that Kounis syndrome should be considered in the differential diagnosis of acute coronary syndrome.

5.
Tunis Med ; 94(4): 276-283, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27704511

ABSTRACT

Introduction In recent years, many marine resources have drew attention in the research for bio-active compounds to develop new drugs and health foods. (1) Marine algae are now considered as a rich source of antioxidants (2). It is known that seaweeds contain numerous bioactive substances that have the ability to lower cholesterol, reduce blood pressure, promote healthy digestion; and antioxidant activity (3). Natural antioxidants are interesting compounds due to their properties which help prevent oxidative stress (4), among other potentially beneficial actions. For instance, several biological effects have been attributed to flavonoids, such as anti-tumoral, anti-inflammatory, anti-ischemic and anti-aggregate plaquetary activities. These activities are believed to be in part related to the antioxidant properties of the compounds, namely in scavenging radical oxygen species (ROS). (5, 6) The cold ischemia constitute a situation of oxidative stress in touch with liberation of oxygenated radicals, these situations incited the researchers to find means for the improvement of the conservation of organs allowing to prolong the durations of the cold ischemia of certain organs (in particular the liver) with conservation of the maximum functional value. However, the constant efforts led by the teams of transplantation to develop transplants, the conservation of organs remains a problem to be resolved. (7) Conservation solution of organ appears as being a stemming to remedy the fatal effects of the ischemia-reperfusion. For our part, we think that seaweeds have not delivered their secrets and yet especially that the marine environment of the Tunisian coast still remains little exploited in spite of the big variety of the fauna and the flora of the coast. We envisage in this work, to study a sort of seaweed collected on the Tunisian quotation in the region of "Chott Meriem" (North West of Tunisia). The purpose of our work is to estimate the capacity of extracts stemming from the green seaweed Ulva lactuca to improve the conservation solution of organs against the hepatic effects of ischemia.


Subject(s)
Liver , Organ Preservation Solutions/chemistry , Organ Preservation/methods , Ulva/chemistry , Alanine Transaminase/metabolism , Animals , Antioxidants/administration & dosage , Aspartate Aminotransferases/metabolism , Cold Ischemia/methods , Cold Temperature , Hepatocytes , Male , Oxidative Stress/drug effects , Plant Extracts/administration & dosage , Rats , Rats, Wistar , Reperfusion Injury/prevention & control , Tunisia
6.
Tunis Med ; 94(3): 235-43, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27575510

ABSTRACT

INTRODUCTION: During last years, significant progress was made in the comprehension of the hepatic lesions after Ischemia-Reperfusion episode in order to improve the Results in practice clinical. AIM: To avoid or reduce the damage induced by Ischemia-Reperfusion, we developed a model of hepatic Ischemia-Reperfusion with variable periods of reperfusion from 0 to 24 hours.  METHODS: Our study related to rats Wistar males.  Six various groups were studied: the first reference group (without neither ischemia and reperfusion), the second group with ischemia of 90 min and without reperfusion and the 3end , 4end, 5end and 6end groups in addition to ischemia, underwent a reperfusion of 30 min, 2h, 6h and 24h respectively.  The damage of hepatic Ischemia-Reperfusion was evaluated by a biochemical test based on the proportioning of transaminases and an anatomopathologic study by optical microscopy for the determination of the degree of hepatic attack.  RESULTS: The RESULTS obtained seem to show an aggravation of the liver lesions and an increase in the plasmatic rates of AST and ALT in relation with the duration of the reperfusion.  Indeed, the maximum of damage was observed after 2 hours of reperfusion. We observed a reduction in the lesions after 6h and 24h of reperfusion.  CONCLUSION: Our work enabled us to describe a simple model of hepatic Ischemia-Reperfusion with functional, biochemical and anatomopathologic tests.


Subject(s)
Liver/blood supply , Reperfusion Injury , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Male , Models, Animal , Rats, Wistar
9.
Ann Biol Clin (Paris) ; 73(6): 717-22, 2015.
Article in French | MEDLINE | ID: mdl-26635051

ABSTRACT

Ciclosporine (CsA) is an immunosuppressant drug used in bone marrow transplantation in order to extend allograft survival. Despite its efficiency, CsA can expose to therapeutic failure or to toxicity because of underdosing or overdosage. So, many techniques of monitoring CsA in blood were used, the referance one is the chromatographic technique then, the automated techniques: fluorescence polarization immunoassay (FPIA) and chimiluminescent microparticle immunoassay (CMIA). In this study, we aimed to compare the results of CsA concentrations measured by the two automised techniques. Statistical studies showed that the two techniques were repeatable and reproductible. Results obtained by FPIA were slightly higher than those obtained by CMIA but without a significative difference. In conclusion, FPIA technique could be used to measure CsA blood concentration in replacement of CMIA in case of technical problems.


Subject(s)
Blood Chemical Analysis , Cyclosporine/therapeutic use , Drug Monitoring/methods , Immunosuppressive Agents/therapeutic use , Luminescent Measurements/methods , Blood Chemical Analysis/instrumentation , Blood Chemical Analysis/methods , Blood Chemical Analysis/standards , Drug Monitoring/instrumentation , Drug Monitoring/standards , Fluorescence Polarization Immunoassay/instrumentation , Fluorescence Polarization Immunoassay/methods , Fluorescence Polarization Immunoassay/standards , Humans , Immunoassay/instrumentation , Immunoassay/methods , Immunoassay/standards , Luminescent Measurements/instrumentation , Luminescent Measurements/standards , Pharmacovigilance , Quality Control , Reproducibility of Results , Sensitivity and Specificity
11.
Therapie ; 70(5): 415-24, 2015.
Article in French | MEDLINE | ID: mdl-26071142

ABSTRACT

INTRODUCTION: Valproic acid (VA) is a widely used antiepileptic drug. Because of its pharmacokinetic variability and the influence of intrinsic and extrinsic factors such as the treatment compliance, VA therapeutic drug monitoring (TDM) is recommended in children. The aim of this study is to evaluate the effect of treatment compliance and the economic level on VA tough plasmatic concentration (TPC) and epileptic rhythm in children. MATERIAL AND METHODS: A one-year prospective study (August 2008-August 2009) concerning children (age≤5 years) regularly treated by VA who had a VA TDM. So, 276 plasmatic samples from 238 children were collected. The children were divided in two groups as following: the group 1 (G1) presenting a good compliance and a reliable questioning and the group 2 (G2) presenting a bad compliance and a non reliable questioning. We evaluated the interindividual variability by correlating the TPC to the dose. Then, we divided the hole group in function of their economic levels (low-medium-high). RESULTS: Sex ratio male/female was 1.3. Median age was 5 years+/-3,9. The mean TPC was 62 µg/mL [0.12-131 µg/mL]. VA TPC were in the therapeutic range (TR) in 62%. Adverse drug reactions were noted in 4.2% of the children. G1 represented 70% of the children and G2, 30%. The TPC were in the TR in 67% of G1 and 51% of G2 (p=0.02). There was a significant difference between the TPC in G1 and G2 (p=0.02).There was no significative difference in the TPC in function of the economic levels. There was no correlation between TPC and the administered doses. The epileptic seizures were more spaced in children with therapeutic TPC than those with TPC in the TR (p=0.002) and in G1 than in G2 (p=0.03). CONCLUSIONS: Compliance should be appropriate in order to optimize the TDM rule. A good compliance and a therapeutic TPC allow a better control of epileptic seizures.


Subject(s)
Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Medication Adherence , Valproic Acid/therapeutic use , Anticonvulsants/blood , Anticonvulsants/economics , Anticonvulsants/pharmacokinetics , Child, Preschool , Drug Monitoring , Epilepsy/blood , Female , Humans , Infant , Male , Prospective Studies , Socioeconomic Factors , Surveys and Questionnaires , Treatment Outcome , Tunisia , Valproic Acid/blood , Valproic Acid/economics , Valproic Acid/pharmacokinetics
12.
Curr Drug Saf ; 10(3): 254-6, 2015.
Article in English | MEDLINE | ID: mdl-25968921

ABSTRACT

Tacrolimus is a calcineurin inhibitor primarily metabolized by CYP3A4 and secondarily by CYP3A5. Several drugs can modify tacrolimus blood levels as calcium channel blockers (CCBs). Interaction with nicardipine was reported in some cases. A man with a history of malignant arterial hypertension treated with nicardipine, underwent kidney transplantation. After transplantation, he was treated with tacrolimus, mycophenolate mofetil and corticoids. Therapeutic drug monitoring of tacrolimus was done regularly showing a mean trough concentration (C0) of 24.39 ng/mL with some concentrations reaching 52 ng/mL. After changing nicardipine by prazosine, the first tacrolimus C0 after stopping nicardipine was 3.2 ng/mL. Increase of tacrolimus trough concentrations is due to the inhibition of CYP3A4. Very high levels of tacrolimus suggest the non expression of CYP3A5. Thus, because of the possible lack of the secondary pathway, therapeutic drug monitoring of tacrolimus is highly recommended at the introduction of CCBs and also at its stopping.


Subject(s)
Antihypertensive Agents/adverse effects , Calcium Channel Blockers/adverse effects , Cytochrome P-450 CYP3A Inhibitors/adverse effects , Cytochrome P-450 CYP3A/metabolism , Hypertension/drug therapy , Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation , Nicardipine/adverse effects , Tacrolimus/pharmacokinetics , Antihypertensive Agents/administration & dosage , Biotransformation , Calcium Channel Blockers/administration & dosage , Cytochrome P-450 CYP3A Inhibitors/administration & dosage , Drug Interactions , Drug Monitoring , Drug Substitution , Humans , Hypertension/diagnosis , Hypertension/physiopathology , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/blood , Male , Middle Aged , Nicardipine/administration & dosage , Polypharmacy , Prazosin/administration & dosage , Tacrolimus/administration & dosage , Tacrolimus/blood
13.
Tunis Med ; 93(8-9): 565-8, 2015.
Article in French | MEDLINE | ID: mdl-26815525

ABSTRACT

BACKGROUND: Lamotrigine is an effective anticonvulsant drug used in the treatment of epilepsy. It has a narrow therapeutic range, a large inter and intra-individual pharmacokinetic variability and some concentration-dependent side effects. AIM: The aim of this study was to develop and validate a new method for lamotrigine quantitation in plasma using HPLC with UV/visible detection. METHODS: A rapid HPLC-UV method was developed for the determination of lamotrigine in plasma. All solvents used were HPLC grade. RESULTS: After liquid-liquid extraction, chromatographic separation was achieved using an RP 18 (250 mm) column. The mobile phase was composed of acetonitrile and 0.1 M potassium dihyrogenophosphate (25/75) (v/v). Barbital sodium was used as internal standard. This technique was linear over the 2 µg/mL to 50 µg/mL range (r= 0.99). Detection and quantification limits were 0.07 µg/mL and 0.21 µg/mL, respectively. Within-day coefficient of variation (13.37 to 16 %) and day-to-day coefficients of variation (15.68 to 16.63 %) at three different concentrations. Under these conditions, each analysis required no longer than 10 min. We finally evaluated the plasma concentrations of lamotrigine in Tunisian patients treated with this drug. CONCLUSION: The results found are similar to those previously described and the developed method is repeatable and reproducible. It can be used for clinical applications.


Subject(s)
Anticonvulsants/blood , Chromatography, Liquid/methods , Triazines/blood , Adolescent , Adult , Child , Drug Monitoring/methods , Female , Humans , Lamotrigine , Limit of Detection , Male , Middle Aged , Young Adult
14.
Tunis Med ; 93(12): 760-5, 2015 Dec.
Article in English | MEDLINE | ID: mdl-27249385

ABSTRACT

BACKGROUND: The use of high dose of MTX in the treatment of the leukemia is actually better controlled by renal preparation, control of plasma concentrations and administration of folinic acid. However, High dose MTX has been proven to cause substantial toxicity and have high intra-and inter-patient variability. Population pharmacokinetic analysis is a useful tool for identification of sources of pharmacokinetic variability during anticancer drug development and can aid the design of alternative dosing regimens to enhance their efficacy and safety. AIM: The aim of our study is to developed and validate a population pharmacokinetics model of our population. We hereby describe the clinical covariates (age, sex and clearance of the creatinine) that influence MTX pharmacokinetic for predicting optimal dose to reduce MTX toxicity. METHOD: It is a prospective study achieved between January 2005 to January 2012 in the Service of Clinical Pharmacology. Including 273 patients treated for acute lymphocytic leukaemia 2582 plasma concentration was achieved. The data have been analyzed with Nonmem© software (non linear regression to mixed effect). RESULTS: The age of our patients varied from 2 to 23 years with an average of 13 years. The patients received high dose MTX therapy (1 to 8 g/m2) in 24 hours infusion every 15 days. Three compartiment models describe the pharmacokinetic of MTX. The most important covariables affecting the model were clearance of the creatinine, age and weight. We obtained a good correlation between the predicted and the observed concentrations. CONCLUSION: The development of population pharmacokinetics model of MTX allows us to propose a therapeutic diagram adapted to every patient according to its morphological and pharmacological features while taking in consideration the therapeutic objective.

15.
Hum Vaccin Immunother ; 10(7): 2081-2, 2014.
Article in English | MEDLINE | ID: mdl-25424819

ABSTRACT

The disseminated BCG infection is a rare and serious complication of bacillus Calmette-Guerin (BCG) vaccine. We report a case of probable disseminated BCG infection in a 10-month-old child who had been vaccinated by BCG vaccine at birth. No incident was noted on the first days of vaccination. At the age of 40 days, she developed left supra clavicular and axillar abcessed lymph nodes. She was treated by surgical flattening of the lymph adenopathy. The same lymph node recurred at the age of 6 months and was treated with surgery. Few weeks after the second episode, cutaneous ulcerative lesions appeared. Cutaneous biopsy was performed and showed lesions compatible with tuberculosis. X-rays showed osteolysis of P1 of the middle finger in the left hand. She was treated by anti-tuberculosis antibiotics.


Subject(s)
BCG Vaccine/administration & dosage , BCG Vaccine/adverse effects , Mycobacterium bovis/isolation & purification , Tuberculosis/diagnosis , Tuberculosis/microbiology , Bone and Bones/diagnostic imaging , Bone and Bones/pathology , Female , Humans , Infant , Radiography , Skin/pathology , Tuberculosis/pathology
16.
Therapie ; 69(6): 529-30, 2014.
Article in English | MEDLINE | ID: mdl-25320941

ABSTRACT

Vancomycin penetrates poorly through the blood-brain barrier. Determination of vancomycin concentration in plasma is recommended. In contrast, its determination in cerebrospinal fluid (CSF) is rarely performed. We report the case of a 74-year-old man with post traumatic meningitis with vancomycin concentration measured in CSF.


Subject(s)
Anti-Bacterial Agents/cerebrospinal fluid , Drug Monitoring/methods , Meningitis, Bacterial/cerebrospinal fluid , Vancomycin/cerebrospinal fluid , Aged , Anti-Bacterial Agents/therapeutic use , Brain Injuries/cerebrospinal fluid , Brain Injuries/drug therapy , Humans , Male , Meningitis, Bacterial/drug therapy , Vancomycin/therapeutic use
17.
J Cancer Res Ther ; 10(2): 274-8, 2014.
Article in English | MEDLINE | ID: mdl-25022377

ABSTRACT

OBJECTIVES: This work is aimed on the study of doxorubicin cardiotoxicity and hepatotoxicity in rats and the evaluation of protective effect of trimetazidine administrated concomitantly with doxorubicin for 3 days. MATERIALS AND METHODS: Male Wistar rats used were subjected to different types of treatment (3 days); A: Control, B: Doxorubicin treatment and C: Trimetazidine and doxorubicin treatment. After sacrifice, tissular distribution of doxorubicin, cardiac scintigraphy, histological examination of the myocardium, and evaluation of liver function were assessed. RESULTS: Obtained results show that doxorubicin has a high affinity to tissues especially the heart. It causes hepatotoxicity and cardiotoxicity marked by a significant increase of aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) levels and drop of the left ventricular ejection fraction (EF LV ) by scintigraphy. Histological examination showed general alteration of myocardium structure. Concomitant administration of trimetazidine attenuates significantly the cardiotoxicity and hepatotoxity induced by doxorubicin. CONCLUSION: We have evaluated the protective effect of trimetazidine on an animal model of doxorubicin-induced cardiotoxicity and hepatotoxicity. The evaluation of these effects were assessed by several means; tissular distribution of doxorubicin, histological examination, assessment of liver function, and EF LV by scintigraphy that characterizes the originality of this study.


Subject(s)
Antibiotics, Antineoplastic/toxicity , Antioxidants/pharmacology , Chemical and Drug Induced Liver Injury , Doxorubicin/toxicity , Trimetazidine/pharmacology , Ventricular Dysfunction, Left/chemically induced , Alanine Transaminase/blood , Animals , Antibiotics, Antineoplastic/pharmacokinetics , Antioxidants/therapeutic use , Aspartate Aminotransferases/blood , Chemical and Drug Induced Liver Injury/blood , Chemical and Drug Induced Liver Injury/prevention & control , Doxorubicin/pharmacokinetics , Drug Screening Assays, Antitumor , Liver/drug effects , Liver/pathology , Male , Myocardium/metabolism , Myocardium/pathology , Rats, Wistar , Stroke Volume/drug effects , Tissue Distribution , Trimetazidine/therapeutic use , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/prevention & control
20.
Indian J Pharmacol ; 46(2): 201-6, 2014.
Article in English | MEDLINE | ID: mdl-24741194

ABSTRACT

OBJECTIVES: The primary aim of this study was to establish the population pharmacokinetic (PPK) model of bupivacaine after combined lumbar plexus and sciatic nerve blocks and secondary aim is to assess the effect of patient's characteristics including age, body weight and sex on pharmacokinetic parameters. MATERIALS AND METHODS: A total of 31 patients scheduled for elective lower extremity surgery with combined lumbar and sciatic nerve block using plain bupivacaine 0.5% were included. The total bupivacaine plasma concentrations were measured before injection and after two blocks placement and at selected time points. Monitoring of bupivacaine was made by high performance liquid chromatography (HPLC) with ultraviolet detection. Non-linear mixed effects modeling was used to analyze the PPK of bupivacaine. RESULTS: One compartment model with first order absorption, two input compartments and a central elimination was selected. The Shapiro-Wilks test of normality for normalized prediction distribution errors for this model (P = 0.156) showed this as a valid model. The selected model predicts a population clearance of 930 ml/min (residual standard error [RSE] = 15.48%, IC 95% = 930 ± 282.24) with inter individual variability of 75.29%. The central volume of distribution was 134 l (RSE = 12.76%, IC = 134 ± 33.51 L) with inter individual variability of 63.40%. The absorption of bupivacaine in two sites Ka1 and Ka2 were 0.00462/min for the lumbar site and 0.292/min for the sciatic site. Age, body weight and sex have no effect on the bupivacaine pharmacokinetics in this studied population. CONCLUSION: The developed model helps us to assess the systemic absorption of bupivacaine at two injections sites.


Subject(s)
Anesthetics, Local/pharmacokinetics , Bupivacaine/pharmacokinetics , Lumbosacral Plexus/drug effects , Models, Biological , Nerve Block/methods , Anesthetics, Local/administration & dosage , Anesthetics, Local/blood , Anesthetics, Local/therapeutic use , Bupivacaine/administration & dosage , Bupivacaine/blood , Bupivacaine/therapeutic use , Humans , Lumbosacral Plexus/metabolism , Sciatic Nerve/drug effects , Sciatic Nerve/metabolism , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...